JP2020508066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508066A5 JP2020508066A5 JP2019546141A JP2019546141A JP2020508066A5 JP 2020508066 A5 JP2020508066 A5 JP 2020508066A5 JP 2019546141 A JP2019546141 A JP 2019546141A JP 2019546141 A JP2019546141 A JP 2019546141A JP 2020508066 A5 JP2020508066 A5 JP 2020508066A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- cells
- domain
- heterologous chimeric
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 104
- 108020001507 fusion proteins Proteins 0.000 claims description 104
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 25
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 108010042215 OX40 Ligand Proteins 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 230000000259 anti-tumor effect Effects 0.000 claims description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000001506 immunosuppresive effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 108010029697 CD40 Ligand Proteins 0.000 claims description 5
- 102100032937 CD40 ligand Human genes 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 210000000225 synapse Anatomy 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 230000037453 T cell priming Effects 0.000 claims description 2
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 210000005008 immunosuppressive cell Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004941 influx Effects 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 230000005909 tumor killing Effects 0.000 claims description 2
- 101710102027 V-set and immunoglobulin domain-containing protein 8 Proteins 0.000 claims 13
- 102100038355 V-set and immunoglobulin domain-containing protein 8 Human genes 0.000 claims 13
- 102000004473 OX40 Ligand Human genes 0.000 claims 9
- 230000002045 lasting effect Effects 0.000 claims 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 10
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- -1 LIGHT Proteins 0.000 description 2
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 2
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 2
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000050320 human TNFRSF4 Human genes 0.000 description 1
- 102000057058 human VSIR Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023036738A JP2023071979A (ja) | 2017-02-27 | 2023-03-09 | Ｖｓｉｇ８ベースのキメラタンパク質 |
| JP2025020276A JP2025065443A (ja) | 2017-02-27 | 2025-02-10 | Ｖｓｉｇ８ベースのキメラタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762463999P | 2017-02-27 | 2017-02-27 | |
| US62/463,999 | 2017-02-27 | ||
| PCT/US2018/020038 WO2018157163A1 (en) | 2017-02-27 | 2018-02-27 | Vsig8-based chimeric proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023036738A Division JP2023071979A (ja) | 2017-02-27 | 2023-03-09 | Ｖｓｉｇ８ベースのキメラタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508066A JP2020508066A (ja) | 2020-03-19 |
| JP2020508066A5 true JP2020508066A5 (enExample) | 2021-04-08 |
| JP7244428B2 JP7244428B2 (ja) | 2023-03-22 |
Family
ID=63253418
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546141A Active JP7244428B2 (ja) | 2017-02-27 | 2018-02-27 | Ｖｓｉｇ８ベースのキメラタンパク質 |
| JP2023036738A Pending JP2023071979A (ja) | 2017-02-27 | 2023-03-09 | Ｖｓｉｇ８ベースのキメラタンパク質 |
| JP2025020276A Withdrawn JP2025065443A (ja) | 2017-02-27 | 2025-02-10 | Ｖｓｉｇ８ベースのキメラタンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023036738A Pending JP2023071979A (ja) | 2017-02-27 | 2023-03-09 | Ｖｓｉｇ８ベースのキメラタンパク質 |
| JP2025020276A Withdrawn JP2025065443A (ja) | 2017-02-27 | 2025-02-10 | Ｖｓｉｇ８ベースのキメラタンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11192933B2 (enExample) |
| EP (2) | EP3585410B9 (enExample) |
| JP (3) | JP7244428B2 (enExample) |
| CN (2) | CN118184797A (enExample) |
| AU (1) | AU2018224852B2 (enExample) |
| CA (1) | CA3054130A1 (enExample) |
| IL (1) | IL268170A (enExample) |
| WO (1) | WO2018157163A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3930851A4 (en) * | 2019-02-28 | 2023-03-29 | Shattuck Labs, Inc. | Combination therapies |
| US20220259281A1 (en) * | 2019-06-21 | 2022-08-18 | Shattuck Labs, Inc. | Chimeric protein expressing t-cells |
| AU2022316889A1 (en) * | 2021-07-26 | 2024-01-25 | Kite Pharma, Inc. | Dnvsig3 and dnvsig8 receptors and methods of using the same |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| JPH07509694A (ja) | 1992-05-14 | 1995-10-26 | ベイラー・カレッジ・オブ・メディシン | 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6004941A (en) | 1993-06-14 | 1999-12-21 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DE69632235T2 (de) | 1995-10-18 | 2004-08-26 | Akzo Nobel N.V. | Newcastle-Krankheitsvirus-Kombinationsimpfstoff |
| US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
| US20110041190A1 (en) | 2002-10-31 | 2011-02-17 | Tykocinski Mark L | Novel chimeric proteins |
| JP4723782B2 (ja) | 2000-01-03 | 2011-07-13 | ティーアール アソシエイツ，エル．エル．シー． | 新規なキメラ蛋白質及び該蛋白質の使用方法 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| IL164376A0 (en) * | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| AU2009223784A1 (en) | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| WO2010005519A1 (en) | 2008-06-30 | 2010-01-14 | University Of Pennsylvania | Fn14/trail fusion proteins |
| US20110177070A1 (en) | 2008-07-02 | 2011-07-21 | Emergent Product Development Seatlle, LLC | TGF-Beta Antagonist Multi-Target Binding Proteins |
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| CN102421913A (zh) | 2009-03-13 | 2012-04-18 | 宾夕法尼亚大学董事会 | Ox40/trail融合蛋白 |
| JP5883384B2 (ja) * | 2009-08-13 | 2016-03-15 | ザ ジョンズ ホプキンス ユニバーシティー | 免疫機能を調節する方法 |
| IL300733B1 (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| CA2794483C (en) | 2010-03-26 | 2020-07-07 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
| US20180237525A9 (en) | 2010-03-26 | 2018-08-23 | Randolph J. Noelle | VISTA Agonist and Methods of Use |
| AU2011309689B2 (en) | 2010-09-28 | 2015-01-15 | Hadasit Medical Research Services & Development Ltd. | Compositions and methods for treatment of hematological malignancies |
| US9029315B2 (en) | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
| US10179164B2 (en) | 2011-05-25 | 2019-01-15 | Cel-Sci Corporation | Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
| PE20141520A1 (es) | 2011-07-29 | 2014-11-17 | Univ Pennsylvania | Receptores coestimuladores de cambio |
| EA035323B1 (ru) * | 2012-01-12 | 2020-05-28 | Биовератив Терапьютикс Инк. | Полипептиды химерного фактора viii и их применение |
| AU2012369202A1 (en) | 2012-02-06 | 2014-09-25 | Providence Health & Services - Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| EP4219536A3 (en) | 2012-04-30 | 2023-08-23 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| EP4053162A1 (en) | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| WO2013184912A2 (en) * | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
| TWI677507B (zh) | 2012-06-22 | 2019-11-21 | 達特茅斯學院基金會 | 新穎之ｖｉｓｔａ－ｉｇ構築體及ｖｉｓｔａ－ｉｇ用於治療自體免疫、過敏及發炎病症之用途 |
| CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| EP2892558B1 (en) | 2012-09-07 | 2019-04-10 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
| JP6335189B2 (ja) | 2012-12-17 | 2018-05-30 | トリリアム・セラピューティクス・インコーポレイテッドＴｒｉｌｌｉｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ＳＩＲＰアルファ−Ｆｃ融合体でのＣＤ４７＋疾患細胞の治療 |
| CA2896989A1 (en) | 2013-01-01 | 2014-07-10 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| EP2951209A4 (en) | 2013-01-31 | 2016-06-22 | Univ Jefferson | CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF |
| US9873747B2 (en) | 2013-01-31 | 2018-01-23 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| US9657082B2 (en) | 2013-01-31 | 2017-05-23 | Thomas Jefferson University | PD-L1 and PD-L2-based fusion proteins and uses thereof |
| WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| EP2951199A4 (en) | 2013-01-31 | 2016-07-20 | Univ Jefferson | Fusion proteins for the modulation of regulatory and effector T cells |
| KR20210108497A (ko) | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| PT2970512T (pt) | 2013-03-12 | 2019-01-17 | Biocon Ltd | Proteínas de fusão imunomoduladoras e métodos para produção das mesmas |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| MX2016007965A (es) | 2013-12-17 | 2016-10-28 | Genentech Inc | Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1. |
| AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| CA2936244A1 (en) | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| BR112016027845A2 (pt) | 2014-05-29 | 2017-10-31 | Medimmune Llc | proteínas de fusão de ox40l e usos das mesmas |
| WO2015200828A1 (en) | 2014-06-27 | 2015-12-30 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
| EP3482766B1 (en) | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| WO2016024021A1 (en) | 2014-08-15 | 2016-02-18 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
| MX2017006320A (es) | 2014-11-17 | 2017-08-10 | Genentech Inc | Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1. |
| AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
| MA41460A (fr) * | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| SG11201705844SA (en) * | 2015-02-06 | 2017-08-30 | Heat Biologics Inc | Vector co-expressing vaccine and costimulatory molecules |
| CN116063566A (zh) * | 2015-10-01 | 2023-05-05 | 热生物制品有限公司 | 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法 |
| WO2018027042A1 (en) | 2016-08-03 | 2018-02-08 | Bio-Techne Corporation | Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy |
-
2018
- 2018-02-27 US US16/484,854 patent/US11192933B2/en active Active
- 2018-02-27 AU AU2018224852A patent/AU2018224852B2/en not_active Expired - Fee Related
- 2018-02-27 WO PCT/US2018/020038 patent/WO2018157163A1/en not_active Ceased
- 2018-02-27 EP EP18757138.5A patent/EP3585410B9/en active Active
- 2018-02-27 JP JP2019546141A patent/JP7244428B2/ja active Active
- 2018-02-27 EP EP23176998.5A patent/EP4249503A3/en active Pending
- 2018-02-27 CA CA3054130A patent/CA3054130A1/en active Pending
- 2018-02-27 CN CN202410306323.7A patent/CN118184797A/zh active Pending
- 2018-02-27 CN CN201880010430.8A patent/CN110290798B/zh active Active
-
2019
- 2019-07-18 IL IL268170A patent/IL268170A/en unknown
- 2019-10-28 US US16/665,803 patent/US11192934B2/en active Active
-
2021
- 2021-11-01 US US17/516,006 patent/US11834488B2/en active Active
-
2023
- 2023-03-09 JP JP2023036738A patent/JP2023071979A/ja active Pending
- 2023-10-24 US US18/492,982 patent/US20240067698A1/en not_active Abandoned
-
2025
- 2025-02-10 JP JP2025020276A patent/JP2025065443A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508068A5 (enExample) | ||
| JP7386277B2 (ja) | 二重特異性シグナル伝達物質およびその使用 | |
| JP2020508329A5 (enExample) | ||
| IL258029B (en) | Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins | |
| JP2020508063A5 (enExample) | ||
| EP2019857B1 (en) | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity | |
| CN104114233B (zh) | 转换共刺激受体 | |
| US20160347814A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| JP2021533161A (ja) | Ｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質ならびに使用方法 | |
| WO2019201161A1 (zh) | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 | |
| EP3802581A1 (en) | Multi-specific binding proteins and improvements thereon | |
| JP2018529363A5 (enExample) | ||
| JP2020510653A (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２、ｃｅａまたはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| KR20190115469A (ko) | Bcma, nkg2d 및 cd16에 결합하는 단백질 | |
| CN110114368A (zh) | 靶向突变干扰素-γ及其用途 | |
| JP2020508066A5 (enExample) | ||
| JP5745577B2 (ja) | Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 | |
| CN102203132A (zh) | Pd-1拮抗剂的组合物和使用方法 | |
| JP2021520229A (ja) | 抗ｇｕｃｙ２ｃキメラ抗原受容体の組成物および方法 | |
| CN109195988A (zh) | 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物 | |
| JP2022527643A (ja) | がん治療のための免疫療法 | |
| CN114786701A (zh) | 用于治疗癌症的包括包含il-2蛋白和cd80蛋白的融合蛋白和免疫检查点抑制剂的药物组合物 | |
| CN110475857B (zh) | 表达抗-可替宁嵌合抗原受体的天然杀伤细胞 | |
| KR20220050835A (ko) | 암 치료에 사용하기 위한 면역 체크포인트 억제제와 조합된 펩타이드 | |
| TWI823402B (zh) | 多特異性單域抗體嵌合抗原受體及t細胞銜接體、核酸、其表達細胞、其用途以及治療癌症之醫藥組合物 |